COR1167
A Phase 1, Dose-Escalating, Randomized, Placebo-Controlled, 3-Part Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of COR-1167 in Healthy Subjects and Subjects with Chronic Heart Failure
- Stadium
- inclusie
- Middel
- COR-1167
- Populatie
- Hartfalen
- Fase
- I
- First Patient In
- 7 mei 2024
- Last Patient In
- 1 december 2025
- Last Patient Last Visit
- 25 december 2025
Inclusieperiode, nog 2 dagen over
National Lead
prof. dr. A. Voors
Cardioloog
Contact Bestuur
dr. S. van Wijk
Cardioloog
Contact Kantoor
